


IPW

Patent Docket P1192-2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Sherman Fong Serial No.: 10/791,618 Filed: March 2, 2004 For: Novel Polypeptides and Nucleic Acids Encoding Bokekeine	Group Art Unit: Unknown Examiner: Unknown Confirmation No: 4005 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 29, 2005  Teri Lee
---	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution

in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/816,920, filed March 22, 2001 and relied upon in this application for an earlier filing date under 35 USC §120.

☐ **BLAST results enclosed:**

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-0" (nucleotide) and "BLAST Results B-1 - B-0" (protein) on the PTO

Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: April 29, 2005

By: 

David A. Carpenter, Ph.D.

Reg. No. 45,945

Telephone No. (650) 225-3733

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1192-2C1

Serial No.

10/791,618

LIST OF DISCLOSURES SUBMITTED BY APPLICANT

(Use several sheets if necessary)

Applicant

Sherman Fong

Filing Date

02 Mar 2004

Group

Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	1	5910431	Ni, et al.			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 2	Baggiolini et al., "Interleukin-8 and Related Chemotactic Cytokines - CXC and CC Chemokines" <u>Adv Immunology</u> 55:97-179 (1994)
* 3	Coligan et al, eds., "Proliferative Assays for T Cell Function" <u>Current Protocols in Immunology</u> , John Wiley & Sons, Inc., Chapter 3.12, Vol. 1 (1991)
* 4	Lu and Gillett, "An Optimized Protocol for In Situ Hybridization Using PCR-Generated ³³ P-Labeled Riboprobes." <u>Cell Vision</u> . 1(2):169-176 (1994)
* 5	McMaster et al., "Human Placental HLA-G Expression Is Restricted to Differentiated Cytotrophoblasts" <u>J. Immunol.</u> 154(8):3771-3778 (1995)
* 6	Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" <u>Protein Engineering</u> . 10(1):1-6 (1997)
* 7	Paul, W.E. ed. <u>Fundamental Immunology</u> , Raven Press, NY, 3rd edition pps. 822-826 (1993)
* 8	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
* 9	Strieter et al., "The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis" <u>Journal of Biological Chemistry</u> 270:27348-27357 (1995)
*10	Thomson A. <u>The Cytokine Handbook</u> , Academic Press, NY, 2nd edition (1994)
*11	von Heijne, G., "A new method for predicting signal sequence cleavage sites" <u>Nucleic Acids Research</u> 14:4683-4690 (1986)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.